India's Income Tax Department Tightens Noose Over Sanofi-Aventis' Shantha Biotech Deal; Claim Tax On Deal Made Over An "Indian" Asset

MUMBAI - Sanofi-Aventis is faced with more headwinds in India even as it tries to absorb the negative impact of the recent delisting of Shan 5 - its popular pentavalent vaccine - by the World Health Organization